EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma

Brandon Tedder, Manisha Bhutani

Cells · 15.07.2025 · 14 (14) · 1077

DOI: 10.3390/cells14141077 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 15.07.2025. Verfasst von Brandon Tedder und 1 weiteren Autor:innen. Beteiligte Einrichtung: Advocate Health Levine Cancer Institute, Charlotte, NC 28204, USA. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Multiple Myeloma, B-Cell Maturation Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B-cell maturation antigen (BCMA)-targeted therapies including both chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies (BsAbs), have revolutionized the treatment landscape for relapsed/refractory multiple myeloma (MM), offering both deep and durable responses, even in heavily pretreated patients. Despite these advances, most patients ultimately experience relapse. This is likely related to the development of resistance mechanisms that limit the long-term efficacy and durability of BCMA-targeted approaches. In this review, we examine the current landscape of BCMA-directed therapies, including Idecabtagene Vileucel, Ciltacabtagene Autoleucel, Teclistamab, and Elranatamab and explore the multifactorial mechanisms driving resistance. These mechanisms include tumor-intrinsic factors, host-related and tumor-extrinsic factors, and factors related to the tumor-microenvironment itself. We outline emerging strategies to overcome resistance, such as dual-targeting therapies, γ-secretase inhibitors, immune-checkpoint blockade, armored CAR T constructs, and novel combination regimens. Additionally, we discuss the role of therapy sequencing, emphasizing how prior exposure to BsAbs or CAR T-cell therapies may influence the efficacy of subsequent treatments. A deeper understanding of resistance biology, supported by integrated immune and genomic profiling, is essential to optimizing therapeutic durability and ultimately improve patient outcomes for patients with MM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificMultiple MyelomaB-Cell Maturation AntigenImmunotherapy, AdoptiveDrug Resistance, NeoplasmReceptors, Chimeric AntigenHumans

Stichwörter der Autor:innen

BCMACAR-T cell therapiesT-cell exhaustionantigen escapebispecific antibodiesimmunotherapymultiple myelomatumor microenvironment

Substanzen

Antibodies, BispecificB-Cell Maturation AntigenReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Advocate Health Levine Cancer Institute, Charlotte, NC 28204, USA.

Zitieren

APA

Tedder, B., & Bhutani, M. (2025). Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma. Cells, 14(14), 1077. https://doi.org/10.3390/cells14141077

Vancouver

Tedder B, Bhutani M. Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma. Cells. 2025;14(14):1077. doi:10.3390/cells14141077

BibTeX
@article{Tedder2025,
  author = {Tedder, Brandon and Bhutani, Manisha},
  title = {Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {14},
  pages = {1077},
  doi = {10.3390/cells14141077}
}
Kostenlos starten →